Association Between Testosterone Levels and COPD Severity
NCT ID: NCT02824809
Last Updated: 2016-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2016-06-30
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diurnal Testosterone Concentration
NCT03091296
BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC
NCT05530395
Survey of Testosterone Levels in Male Cancer Patients
NCT00483418
Study to Evaluate the Association of Testosterone Levels With Coronary Artery Calcification
NCT02310659
Testosterone Effects on Bone and Frailty
NCT00182871
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COPD defined according to clinical diagnosis and spirometry American thoracic society ( ATS) criteria
* Stable COPD without recent acute exacerbation (less than 2 weeks)
Exclusion Criteria
* Those who are under treatment with testosterone replacement or anti-androgens
* Comorbidities: Cirrhosis, Alcoholism, cryptorchidism, panhypopituitarism, Pituitary adenoma.
* Orchiectomy
* Systemic glucocorticoids (equivalent dose ≥ 4 mg of prednisone in the last 3 weeks).
* Relative and absolute contraindications for spirometry.
45 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asociacion Argentina Medicina Respiratoria (AAMR)
UNKNOWN
Hospital Italiano de Buenos Aires
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Horacio Matias Castro
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Horacio M Castro, MD
Role: PRINCIPAL_INVESTIGATOR
HIBA, Buenos Aires Argentina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Italiano de Buenos Aires
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2413
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.